Stockscreener 앱 받기
58.71
0.53%
-0.31
시간 외 거래:
58.35
-0.36
-0.61%
전일 마감가:
$59.02
열려 있는:
$58.86
하루 거래량:
6.74M
Relative Volume:
0.55
시가총액:
$119.87B
수익:
$48.19B
순이익/손실:
$7.06B
주가수익비율:
16.97
EPS:
3.4587
순현금흐름:
$12.85B
1주 성능:
-2.43%
1개월 성능:
+2.30%
6개월 성능:
+33.95%
1년 성능:
+20.58%
1일 변동 폭
$58.34
$59.21
1주일 범위
$57.79
$60.12
52주 변동 폭
$42.52
$62.89
브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile
명칭
Bristol Myers Squibb Co
전화
(609) 252-4621
주소
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
58.71 | 119.87B | 48.19B | 7.06B | 12.85B | 3.4587 |
LLY
Lilly Eli Co
|
883.96 | 789.69B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
227.50 | 547.64B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
198.71 | 351.47B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
189.75 | 294.27B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
145.47 | 277.58B | 54.72B | 14.02B | 15.32B | 7.1855 |
브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-12-12 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 개시 | Piper Sandler | Overweight |
| 2024-12-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-13 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-07-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2024-02-06 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-07-10 | 개시 | SVB Securities | Market Perform |
| 2023-06-28 | 개시 | Daiwa Securities | Outperform |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-01-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 개시 | Credit Suisse | Neutral |
| 2022-10-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-06-03 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Underweight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-01 | 다운그레이드 | Argus | Buy → Hold |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | 업그레이드 | Truist | Hold → Buy |
| 2020-11-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-11-06 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2020-10-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-07-28 | 개시 | Raymond James | Outperform |
| 2020-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-06 | 재개 | Citigroup | Buy |
| 2019-12-13 | 업그레이드 | Argus | Hold → Buy |
| 2019-11-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-08-14 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2019-05-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 재개 | JP Morgan | Overweight |
| 2019-01-15 | 업그레이드 | Societe Generale | Sell → Buy |
| 2018-10-22 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스
9 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Bristol Myers Squibb-Pfizer Alliance to sell Eliquis on Mark Cuban’s Cost Plus Drugs - ROI-NJ
Bristol Myers Squibb (BMY) and Pfizer (PFE) Launch Eliquis on Co - GuruFocus
Bristol Myers Squibb Becomes Stable Choice for Defensive Portfolios - HarianBasis.co
Bristol-Myers Squibb Company (BMY): Favorite for Conservative Portfolios - Insider Monkey
Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy - Reuters
Milestone in Atrium and BMS cardiovascular collaboration - BioWorld News
Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company - Yahoo Finance
Bristol Myers Squibb: Strong Pipeline, Weak Outlook (Rating Downgrade) - Seeking Alpha
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MSN
Multi-Manager Large Cap Growth Strategies Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
MFS Global Alternative Strategy Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb donates lab equipment to Seton Hall - NJBIZ
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Milestone Asset Management LLC Invests $2.25 Million in Bristol Myers Squibb Company $BMY - MarketBeat
Atrium Therapeutics earns $15M from Bristol Myers Squibb - Investing.com
Atrium lands $15M after delivering first heart drug candidate - Stock Titan
Bristol Myers Squibb files WARN notice for 206 jobs - ROI-NJ
Vulvar Cancer Market Global and Regional Analysis Report 2025-2035, Profiles of Merck & Co., Bristol Myers Squibb, and AstraZeneca - GlobeNewswire Inc.
61,789 Shares in Bristol Myers Squibb Company $BMY Bought by CPC Advisors LLC - MarketBeat
Bristol-Myers Squibb Company stock (US0897961004): Why does its oncology dominance matter more now f - AD HOC NEWS
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now? - Yahoo Finance
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock - Yahoo Finance
BMY Expands Partnership with Foundation Medicine for Diagnostic Development - GuruFocus
New cancer test aims to find patients with hard-to-detect MTAP deletion - Stock Titan
Targeted Alpha Therapy Market Landscape Report 2026-2030: Clinical Trials Insights on 30 Drugs - GlobeNewswire Inc.
Oncolytic Virus Immunotherapy Market Landscape Report 2026: A $5 Opportunity by 2031 - GlobeNewswire Inc.
Bristol-Myers Squibb stock (US1078421011): Is its oncology dominance strong enough to unlock new ups - AD HOC NEWS
Lobbying Update: $1,320,000 of BRISTOL-MYERS SQUIBB COMPANY lobbying was just disclosed - Quiver Quantitative
AQR Equity Market Neutral Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
Can BMY's Growth Portfolio Counter Legacy Drugs Decline in Q1? - TradingView
Why Bristol Myers Squibb (BMY) is a Top Momentum Stock for the Long-Term - Yahoo Finance
The top 20 pharma companies by 2025 revenue - Fierce Pharma
BMY Technical Analysis | Trend, Signals & Chart Patterns | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Bristol Myers Squibb Stock Forecast: What’s Driving Focus - Kalkine Media
Assetmark Inc. Lowers Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb to cut 206 more jobs in New Jersey (updated) - NJBIZ
Bristol-Myers Squibb Company Solicits Proxies from Shareholders - marketscreener.com
Virtus Silvant Large-Cap Growth Stock Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Why Bristol Myers Squibb (BMY) outpaced the stock market today - MSN
Bristol Myers Squibb Company $BMY Shares Sold by Mirae Asset Global Investments Co. Ltd. - MarketBeat
Bristol Myers Squibb (BMY) Institutional Ownership 2026 $BMY - MarketBeat
Bristol-Myers Squibb Announces the Early Results of its Cash Tender Offer For Up to $400 Million Aggregate Principal Amount o... - ADVFN
Why Bristol Myers Squibb (BMY) Outpaced the Stock Market Today - Yahoo Finance
Bain Capital’s Beeline Medicines Emerges With Assets From Bristol Myers Squibb - citybiz
New Bain biotech startup, building on BMS drugs, gets a name and a CEO - statnews.com
Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers - BioPharma Dive
Raymond James reiterates Market Perform on Bristol-Myers stock - Investing.com
Raymond James reiterates Market Perform on Bristol-Myers stock By Investing.com - Investing.com Canada
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
브리스톨 마이어스 스퀴브 (BMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
2.42%
자본화:
|
볼륨(24시간):